Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCPVax + Atezolizumab + Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT05528952Phase 2Recruiting
- Sponsor
- CHU de Besançon
- Start
- Sep 2022
- Primary completion
- Mar 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of UCPVax in hepatocellular carcinoma (HCC) (2 arms), sponsored by CHU de Besançon. Primary endpoint: Objective Response Rate at 6 months. Started Sep 2022; status: recruiting.
02
Drugs
UCPVax
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05528952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528952.